De Novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation

The 2000-2003 phase II prospective randomized trial

S. K. Asrani, R. H. Wiesner, J. F. Trotter, G. Klintmalm, E. Katz, E. Maller, J. Roberts, N. Kneteman, L. Teperman, J. J. Fung, J. M. Millis

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

We studied whether the use of sirolimus with reduced-dose tacrolimus, as compared to standard-dose tacrolimus, after liver transplantation is safe, tolerated and efficacious. In an international multicenter, open-label, active-controlled randomized trial (2000-2003), adult primary liver transplant recipients (n = 222) were randomly assigned immediately after transplantation to conventional-dose tacrolimus (trough: 7-15 ng/mL) or sirolimus (loading dose: 15 mg, initial dose: 5 mg titrated to a trough of 4-11 ng/mL) and reduced-dose tacrolimus (trough: 3-7 ng/mL). The study was terminated after 21 months due to imbalance in adverse events. The 24-month cumulative incidence of graft loss (26.4% vs. 12.5%, p = 0.009) and patient death (20% vs. 8%, p = 0.010) was higher in subjects receiving sirolimus. A numerically higher rate of hepatic artery thrombosis/portal vein thrombosis was observed in the sirolimus arm (8% vs. 3%, p = 0.065). The incidence of sepsis was higher in the sirolimus arm (20.4% vs. 7.2%, p = 0.006). Rates of acute cellular rejection were similar between the two groups. Early use of sirolimus using a loading dose followed by maintenance doses and reduced-dose tacrolimus in de novo liver transplant recipients is associated with higher rates of graft loss, death and sepsis when compared to the use of conventional-dose tacrolimus alone. This study reports the results of the international, multicenter, controlled randomized trial of adult primary liver transplant recipients receiving de novo sirolimus and reduced dose tacrolimus or conventional dose tacrolimus, which formed the basis of a black box warning for use of sirolimus immediately after liver transplantation. See editorial by Levitsky and Feng on page 249.

Original languageEnglish (US)
Pages (from-to)356-366
Number of pages11
JournalAmerican Journal of Transplantation
Volume14
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Tacrolimus
Sirolimus
Liver Transplantation
Liver
Sepsis
Thrombosis
Arm
Randomized Controlled Trials
Drug Labeling
Transplants
Hepatic Artery
Incidence
Portal Vein
Transplantation
Transplant Recipients

Keywords

  • Black box
  • graft failure
  • hepatic artery thrombosis
  • patient death
  • portal vein thrombosis
  • rapamycin
  • renal failure

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)
  • Medicine(all)

Cite this

De Novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation : The 2000-2003 phase II prospective randomized trial. / Asrani, S. K.; Wiesner, R. H.; Trotter, J. F.; Klintmalm, G.; Katz, E.; Maller, E.; Roberts, J.; Kneteman, N.; Teperman, L.; Fung, J. J.; Millis, J. M.

In: American Journal of Transplantation, Vol. 14, No. 2, 02.2014, p. 356-366.

Research output: Contribution to journalArticle

Asrani, SK, Wiesner, RH, Trotter, JF, Klintmalm, G, Katz, E, Maller, E, Roberts, J, Kneteman, N, Teperman, L, Fung, JJ & Millis, JM 2014, 'De Novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: The 2000-2003 phase II prospective randomized trial', American Journal of Transplantation, vol. 14, no. 2, pp. 356-366. https://doi.org/10.1111/ajt.12543
Asrani, S. K. ; Wiesner, R. H. ; Trotter, J. F. ; Klintmalm, G. ; Katz, E. ; Maller, E. ; Roberts, J. ; Kneteman, N. ; Teperman, L. ; Fung, J. J. ; Millis, J. M. / De Novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation : The 2000-2003 phase II prospective randomized trial. In: American Journal of Transplantation. 2014 ; Vol. 14, No. 2. pp. 356-366.
@article{1d2dc100f35545bf9e9ac145112c7833,
title = "De Novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: The 2000-2003 phase II prospective randomized trial",
abstract = "We studied whether the use of sirolimus with reduced-dose tacrolimus, as compared to standard-dose tacrolimus, after liver transplantation is safe, tolerated and efficacious. In an international multicenter, open-label, active-controlled randomized trial (2000-2003), adult primary liver transplant recipients (n = 222) were randomly assigned immediately after transplantation to conventional-dose tacrolimus (trough: 7-15 ng/mL) or sirolimus (loading dose: 15 mg, initial dose: 5 mg titrated to a trough of 4-11 ng/mL) and reduced-dose tacrolimus (trough: 3-7 ng/mL). The study was terminated after 21 months due to imbalance in adverse events. The 24-month cumulative incidence of graft loss (26.4{\%} vs. 12.5{\%}, p = 0.009) and patient death (20{\%} vs. 8{\%}, p = 0.010) was higher in subjects receiving sirolimus. A numerically higher rate of hepatic artery thrombosis/portal vein thrombosis was observed in the sirolimus arm (8{\%} vs. 3{\%}, p = 0.065). The incidence of sepsis was higher in the sirolimus arm (20.4{\%} vs. 7.2{\%}, p = 0.006). Rates of acute cellular rejection were similar between the two groups. Early use of sirolimus using a loading dose followed by maintenance doses and reduced-dose tacrolimus in de novo liver transplant recipients is associated with higher rates of graft loss, death and sepsis when compared to the use of conventional-dose tacrolimus alone. This study reports the results of the international, multicenter, controlled randomized trial of adult primary liver transplant recipients receiving de novo sirolimus and reduced dose tacrolimus or conventional dose tacrolimus, which formed the basis of a black box warning for use of sirolimus immediately after liver transplantation. See editorial by Levitsky and Feng on page 249.",
keywords = "Black box, graft failure, hepatic artery thrombosis, patient death, portal vein thrombosis, rapamycin, renal failure",
author = "Asrani, {S. K.} and Wiesner, {R. H.} and Trotter, {J. F.} and G. Klintmalm and E. Katz and E. Maller and J. Roberts and N. Kneteman and L. Teperman and Fung, {J. J.} and Millis, {J. M.}",
year = "2014",
month = "2",
doi = "10.1111/ajt.12543",
language = "English (US)",
volume = "14",
pages = "356--366",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - De Novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation

T2 - The 2000-2003 phase II prospective randomized trial

AU - Asrani, S. K.

AU - Wiesner, R. H.

AU - Trotter, J. F.

AU - Klintmalm, G.

AU - Katz, E.

AU - Maller, E.

AU - Roberts, J.

AU - Kneteman, N.

AU - Teperman, L.

AU - Fung, J. J.

AU - Millis, J. M.

PY - 2014/2

Y1 - 2014/2

N2 - We studied whether the use of sirolimus with reduced-dose tacrolimus, as compared to standard-dose tacrolimus, after liver transplantation is safe, tolerated and efficacious. In an international multicenter, open-label, active-controlled randomized trial (2000-2003), adult primary liver transplant recipients (n = 222) were randomly assigned immediately after transplantation to conventional-dose tacrolimus (trough: 7-15 ng/mL) or sirolimus (loading dose: 15 mg, initial dose: 5 mg titrated to a trough of 4-11 ng/mL) and reduced-dose tacrolimus (trough: 3-7 ng/mL). The study was terminated after 21 months due to imbalance in adverse events. The 24-month cumulative incidence of graft loss (26.4% vs. 12.5%, p = 0.009) and patient death (20% vs. 8%, p = 0.010) was higher in subjects receiving sirolimus. A numerically higher rate of hepatic artery thrombosis/portal vein thrombosis was observed in the sirolimus arm (8% vs. 3%, p = 0.065). The incidence of sepsis was higher in the sirolimus arm (20.4% vs. 7.2%, p = 0.006). Rates of acute cellular rejection were similar between the two groups. Early use of sirolimus using a loading dose followed by maintenance doses and reduced-dose tacrolimus in de novo liver transplant recipients is associated with higher rates of graft loss, death and sepsis when compared to the use of conventional-dose tacrolimus alone. This study reports the results of the international, multicenter, controlled randomized trial of adult primary liver transplant recipients receiving de novo sirolimus and reduced dose tacrolimus or conventional dose tacrolimus, which formed the basis of a black box warning for use of sirolimus immediately after liver transplantation. See editorial by Levitsky and Feng on page 249.

AB - We studied whether the use of sirolimus with reduced-dose tacrolimus, as compared to standard-dose tacrolimus, after liver transplantation is safe, tolerated and efficacious. In an international multicenter, open-label, active-controlled randomized trial (2000-2003), adult primary liver transplant recipients (n = 222) were randomly assigned immediately after transplantation to conventional-dose tacrolimus (trough: 7-15 ng/mL) or sirolimus (loading dose: 15 mg, initial dose: 5 mg titrated to a trough of 4-11 ng/mL) and reduced-dose tacrolimus (trough: 3-7 ng/mL). The study was terminated after 21 months due to imbalance in adverse events. The 24-month cumulative incidence of graft loss (26.4% vs. 12.5%, p = 0.009) and patient death (20% vs. 8%, p = 0.010) was higher in subjects receiving sirolimus. A numerically higher rate of hepatic artery thrombosis/portal vein thrombosis was observed in the sirolimus arm (8% vs. 3%, p = 0.065). The incidence of sepsis was higher in the sirolimus arm (20.4% vs. 7.2%, p = 0.006). Rates of acute cellular rejection were similar between the two groups. Early use of sirolimus using a loading dose followed by maintenance doses and reduced-dose tacrolimus in de novo liver transplant recipients is associated with higher rates of graft loss, death and sepsis when compared to the use of conventional-dose tacrolimus alone. This study reports the results of the international, multicenter, controlled randomized trial of adult primary liver transplant recipients receiving de novo sirolimus and reduced dose tacrolimus or conventional dose tacrolimus, which formed the basis of a black box warning for use of sirolimus immediately after liver transplantation. See editorial by Levitsky and Feng on page 249.

KW - Black box

KW - graft failure

KW - hepatic artery thrombosis

KW - patient death

KW - portal vein thrombosis

KW - rapamycin

KW - renal failure

UR - http://www.scopus.com/inward/record.url?scp=84895060297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895060297&partnerID=8YFLogxK

U2 - 10.1111/ajt.12543

DO - 10.1111/ajt.12543

M3 - Article

VL - 14

SP - 356

EP - 366

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 2

ER -